Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)
Newborn bloodspot screening (NBS) for cystic fibrosis (CF) is an effective strategy for the early recognition of infants with a CF diagnosis. Some infants with a positive NBS result for CF have an inconclusive diagnosis and evidence suggests the number of these infants is increasing, as more extensi...
Main Authors: | Aditi Sinha, Kevin W. Southern |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2021-09-01
|
Series: | Breathe |
Online Access: | http://breathe.ersjournals.com/content/17/3/210088.full |
Similar Items
-
Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience
by: Chiara Bianchimani, et al.
Published: (2022-08-01) -
International Approaches to Management of CFTR-Related Metabolic Syndrome/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis
by: Jane Chudleigh, et al.
Published: (2022-01-01) -
Inconclusive Diagnosis after Newborn Screening for Cystic Fibrosis
by: Anne Munck
Published: (2020-03-01) -
Cystic fibrosis transmembrane conductance regulator (CFTR): beyond cystic fibrosis
by: Giuseppe Fabio Parisi, et al.
Published: (2022-05-01) -
Psychological Impact on Parents of an Inconclusive Diagnosis Following Newborn Bloodspot Screening for Cystic Fibrosis: A Qualitative Study
by: Faye Johnson, et al.
Published: (2019-06-01)